Home / Market News / $RNXT
benzinga Corporate Catalyst Impact 55/100 ● neutral

RenovoRx Announces Publication Of Peer-Reviewed Case Series In Case Reports In Oncology From Researchers At Hackensack Meridian Health’s Jersey Shore University Medical Center

Oct 1, 2026, 12:39 PM UTC · Primary ticker $RNXT

RenovoRx announced the publication of a peer-reviewed case series demonstrating positive outcomes for its RenovoCath device in treating locally advanced pancreatic cancer. This publication provides clinical validation for the device, potentially boosting investor confidence and future adoption.

RenovoRx announced the publication of a peer-reviewed case series in 'Case Reports in Oncology' detailing the successful use of its RenovoCath device in two patients with locally advanced pancreatic cancer. This publication provides clinical evidence of the device's efficacy, showing tumor treatment response and reduction in cancer markers without major complications. For traders, this is a positive development for RenovoRx as it offers external validation of their technology, which could lead to increased adoption and improved market perception in the short term. Long-term, continued positive clinical data and publications are crucial for the company's growth and competitive positioning in the oncology device market, reducing perceived risk for investors.

$RNXT positive Clinical validation of key product
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.